HomeClinical TopicsFDA announces new risk factor for PML associated with Tysabri

FDA announces new risk factor for PML associated with Tysabri

On Jan. 20, the U.S. Food and Drug Administration (FDA) announced that testing positive for anti-JC virus antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis or Crohn’s disease. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content